BUSPIRONE TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

BUSPIRONE HYDROCHLORIDE

可用日期:

APOTEX INC

ATC代码:

N05BE01

INN（国际名称）:

BUSPIRONE

剂量:

5MG

药物剂型:

TABLET

组成:

BUSPIRONE HYDROCHLORIDE 5MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Prescription

治疗领域:

MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS

產品總結:

Active ingredient group (AIG) number: 0116263002; AHFS:

授权状态:

APPROVED

授权日期:

2020-12-18

产品特点

_BUSPIRONE _
_Page 1 of 40_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
BUSPIRONE
Buspirone Hydrochloride
Tablets, 5 mg and 10 mg, Oral
USP
Anxiolytic
APOTEX INC.
150 Signet Drive
Weston, Ontario
M9L 1T9
Date of Initial Authorization:
FEB 16, 1996
Date of Revision:
OCT 18, 2021
Submission Control Number: 252361
_ _
_BUSPIRONE _
_Page 2 of 40_
RECENT MAJOR LABEL CHANGES
1 Indications, 1.2 Geriatrics
10/2021
2 Contraindications
12/2020
3 Serious warnings and precautions box
10/2021
4 Dosage and administration, 4.1 Dosing Considerations
10/2021
7 Warnings and precautions, General
10/2021
7 Warnings and Precautions, Serotonin Toxicity/Serotonin Syndrome
12/2020
7 Warnings and precautions, Dependence/Tolerance
10/2021
7 Warnings and precautions, Withdrawal
10/2021
7 Warnings and precautions, Falls and Fractures
10/2021
7 Warnings and precautions, 7.1.4 Geriatrics
10/2021
8 Adverse Reactions, 8.5 Post-Market Adverse Reactions
10/2021
9 Drug Interactions
12/2020
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS................................................................................................................
4
1.1
Pediatrics
............................................................................................................
4
1.2
Geriatrics
............................................................................................................
4
2
CONTRAINDICATIONS
..................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS
BOX.........................................